TrialThe Lancet. Oncology2016

Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial.

Sarah B Goldberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.